AI Analysis
AI-generated analysis. Always verify with the original filing.
NeuroSense Therapeutics Ltd. received two Nasdaq non-compliance notifications on April 2, 2026—one for failing to maintain a $1.00 minimum bid price and another for falling below the $35 million minimum market value of listed securities—granting until September 29, 2026 to regain compliance.
Key Takeaways
1Nasdaq notified NeuroSense on April 2, 2026 that its ordinary shares traded below $1.00 for 30 consecutive business days (Feb 18–Mar 31, 2026), violating Rule 5550(a)(2).
2Nasdaq also notified NeuroSense it failed to meet the $35 million minimum market value of listed securities (MVLS) requirement under Rule 5550(b)(2) over the same 30-day period.
3The Company has until September 29, 2026—a 180-calendar-day compliance period—to satisfy both requirements: 10 consecutive business days at ≥$1.00 bid price and ≥$35 million MVLS.
4The notifications have no immediate effect on listing or trading; NRSN ordinary shares and NRSNW warrants continue trading on The Nasdaq Capital Market.